Evidence map›Paper›PMID 38979260›Full record

ArticlebioRxiv : the preprint server for biology2025

Stabilization of GTSE1 by cyclin D1-CDK4/6-mediated phosphorylation promotes cell proliferation: relevance in cancer prognosis.

Nelson García-Vázquez, Tania J González-Robles, Ethan Lane, Daria Spasskaya, Qingyue Zhang, Marc Kerzhnerman, YeonTae Jeong, Marta Collu, Daniele Simoneschi, Kelly V Ruggles and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Nelson García-VázquezDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, NYC, NY, USA.
Tania J González-RoblesDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, NYC, NY, USA.
Ethan LaneDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, NYC, NY, USA.
Daria SpasskayaDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, NYC, NY, USA.
Qingyue ZhangDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, NYC, NY, USA.
Marc KerzhnermanDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, NYC, NY, USA.
YeonTae JeongDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, NYC, NY, USA.
Marta ColluDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, NYC, NY, USA.
Daniele SimoneschiDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, NYC, NY, USA.
Kelly V RugglesDepartment of Medicine, New York University Grossman School of Medicine, NYC, NY, USA.
Gergely RonaDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, NYC, NY, USA.
Sharon KaisariDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, NYC, NY, USA.
Michele PaganoDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, NYC, NY, USA.ORCID 0000-0003-3210-2442

Funding

Project 3: The Evolving Role of Regional Lymph Nodes in Melanoma ProgressionU54CA263001 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Kelly Valentine Ruggles · 2022 to 2026
$11.6M
Training Program in Cell BiologyT32GM136542 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SMITH, SUSAN · 2020 to 2024
$3.0M
Regulation of the cell proliferation by CRL ubiquitin ligases-diversity supplementR35GM136250 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MICHELE PAGANO · 2020 to 2026
$2.7M
NCI NIH HHS U54 CA263001NIGMS NIH HHS R35 GM136250NIGMS NIH HHS T32 GM136542
6 · The paper itself

Abstract

In healthy cells, cyclin D1 is expressed during the G1 phase of the cell cycle, where it activates CDK4 and CDK6. Its dysregulation is a well-established oncogenic driver in numerous human cancers. The cancer-related function of cyclin D1 has been primarily studied by focusing on the phosphorylation of the retinoblastoma (RB) gene product. Here, using an integrative approach combining bioinformatic analyses and biochemical experiments, we show that GTSE1 (G-Two and S phases expressed protein 1), a protein positively regulating cell cycle progression, is a previously unrecognized substrate of cyclin D1-CDK4/6 in tumor cells overexpressing cyclin D1 during G1 and subsequent phases. The phosphorylation of GTSE1 mediated by cyclin D1-CDK4/6 inhibits GTSE1 degradation, leading to high levels of GTSE1 across all cell cycle phases. Functionally, the phosphorylation of GTSE1 promotes cellular proliferation and is associated with poor prognosis within a pan-cancer cohort. Our findings provide insights into cyclin D1's role in cell cycle control and oncogenesis beyond RB phosphorylation.

Indexed as

CDK4CDK6cell proliferationcullin-RING ligasescyclin D1

Identifiers

PMID38979260
PMCPMC11230433

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.